Android Apple

Amphenol Cl A Receives IBD Stock Rating Upgrade

By Investor's Business Daily   |   4 months ago
Amphenol Cl A Receives IBD Stock Rating Upgrade

Discover game-changing stocks by looking for those with a 95+ rating in key metrics early in a price run. Amphenol Cl A is out of buy range with a 93 EPS Rating and 22% earnings growth in Q2.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.